Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)
TipRanks (Tue, 16-Apr 8:21 PM ET)
Genmab Reports Strong Q1 Sales of DARZALEX
TipRanks (Tue, 16-Apr 10:27 AM ET)
J&J sets guidance below consensus as MedTech underperforms
Seeking Alpha News (Tue, 16-Apr 7:20 AM ET)
Genmab Advances Share Buy-back Program
TipRanks (Mon, 15-Apr 9:05 PM ET)
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Globe Newswire (Wed, 3-Apr 1:34 AM ET)
Business Wire (Tue, 27-Feb 7:45 AM ET)
Genmab Announces Initiation of Share Buy-Back Program
Globe Newswire (Wed, 14-Feb 11:41 AM ET)
Genmab Publishes 2023 Annual Report
Globe Newswire (Wed, 14-Feb 11:02 AM ET)
Business Wire (Fri, 2-Feb 6:45 AM ET)
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Genmab A/S - American Depositary Shares trades on the NASDAQ stock market under the symbol GMAB.
As of April 19, 2024, GMAB stock price climbed to $28.56 with 12,126 million shares trading.
GMAB has a beta of 1.00, meaning it tends to be more sensitive to market movements. GMAB has a correlation of 0.18 to the broad based SPY ETF.
GMAB has a market cap of $18.56 billion. This is considered a Large Cap stock.
Last quarter Genmab A/S - American Depositary Shares reported $675 million in Revenue and $.36 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$3.66.
In the last 3 years, GMAB stock traded as high as $49.07 and as low as $26.19.
The top ETF exchange traded funds that GMAB belongs to (by Net Assets): IBB, FBT, AVDE, FENI, DFIC.
GMAB has underperformed the market in the last year with a price return of -31.5% while the SPY ETF gained +22.2%. GMAB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.6% and -3.7%, respectively, while the SPY returned +5.2% and -2.6%, respectively.
GMAB support price is $27.82 and resistance is $28.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GMAB stock will trade within this expected range on the day.